Sang-We Kim

Sang-We Kim

UNVERIFIED PROFILE

Are you Sang-We Kim?   Register this Author

Register author
Sang-We Kim

Sang-We Kim

Publications by authors named "Sang-We Kim"

Are you Sang-We Kim?   Register this Author

100Publications

2637Reads

50Profile Views

Symptom experiences and health-related quality of life among non-small cell lung cancer patients participating in clinical trials.

J Clin Nurs 2019 Jun 18;28(11-12):2111-2123. Epub 2019 Feb 18.

Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jocn.14803DOI Listing
June 2019

Comparison of T790M Acquisition Between Patients Treated with Afatinib and Gefitinib as First-Line Therapy: Retrospective Propensity Score Matching Analysis.

Transl Oncol 2019 Jun 25;12(6):852-858. Epub 2019 Apr 25.

Department of Oncology, Asan Medical Center, College of Medicine, University of Ulsan, Seoul, Republic of Korea. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.tranon.2019.04.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6484288PMC
June 2019

Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study.

Lancet Respir Med 2019 May 10;7(5):437-446. Epub 2019 Apr 10.

Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2213-2600(19)30053-0DOI Listing
May 2019

Modulation of Fexofenadine Pharmacokinetics by Osimertinib in Patients With Advanced EGFR-Mutated Non-Small Cell Lung Cancer.

J Clin Pharmacol 2019 Mar 15. Epub 2019 Mar 15.

QCP, Early Clinical Development, IMED Biotech Unit, AstraZeneca, Waltham, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcph.1403DOI Listing
March 2019

The GTP binding activity of transglutaminase 2 promotes bone metastasis of breast cancer cells by downregulating microRNA-205.

Am J Cancer Res 2019 1;9(3):597-607. Epub 2019 Mar 1.

Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine Seoul 05505, Republic of Korea.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448065PMC
March 2019

Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018).

Authors:
Sneha Berry Nicolas Giraldo Peter Nguyen Benjamin Green Haiying Xu Aleksandra Ogurtsova Abha Soni Farah Succaria Daphne Wang Charles Roberts Julie Stein Elizabeth Engle Drew Pardoll Robert Anders Tricia Cottrell Janis M Taube Ben Tran Mark Voskoboynik James Kuo Yung-Lue Bang Hyun-Cheo Chung Myung-Ju Ahn Sang-We Kim Ayesh Perera Daniel Freeman Ikbel Achour Raffaella Faggioni Feng Xiao Charles Ferte Charlotte Lemech Funda Meric-Bernstam Theresa Werner Stephen Hodi Wells Messersmith Nancy Lewis Craig Talluto Mirek Dostalek Aiyang Tao Sarah McWhirter Damian Trujillo Jason Luke Chunxiao Xu BoMarelli Jin Qi Guozhong Qin Huakui Yu Molly Jenkins Kin-Ming Lo Joern-Peter Halle Yan Lan Matthew Taylor Nicholas Vogelzang Allen Cohn Daniel Stepan Robert Shumaker Corina Dutcus Matthew Guo Emmett Schmidt Drew Rasco Marcia Brose Nicholas Vogelzang Christopher Di Simone Sharad Jain Donald Richards Carlos Encarnacion Drew Rasco Robert Shumaker Corina Dutcus Daniel Stepan Matthew Guo Emmett Schmidt Matthew Taylor Nicholas Vogelzang Carlos Encarnacion Allen Cohn Christopher Di Simone Drew Rasco Donald Richards Matthew Taylor Corina Dutcus Daniel Stepan Robert Shumaker Matthew Guo Emmett Schmidt James Mier Jeongshin An Yeun-Yeoul Yang Won-Hee Lee Jinho Yang Jong-Kyu Kim Hyun Goo Kim Se Hyun Paek Jun Woo Lee Joohyun Woo Jong Bin Kim Hyungju Kwon Woosung Lim Nam Sun Paik Yoon-Keun Kim Byung-In Moon Filip Janku David Tan Juan Martin-Liberal Shunji Takahashi Ravit Geva Ayca Gucalp Xueying Chen Kulandayan Subramanian Jennifer Mataraza Jennifer Wheler Philippe Bedard

J Immunother Cancer 2019 Feb 13;7(1):46. Epub 2019 Feb 13.

Princess Margaret Cancer Centre, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-019-0519-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6373015PMC
February 2019

Non-Small Cell Lung Cancer with Resistance to EGFR-TKI Therapy: CT Characteristics of T790M Mutation-positive Cancer.

Radiology 2018 10 17;289(1):227-237. Epub 2018 Jul 17.

From the Department of Radiology and Research Institute of Radiology (H.J. Koo, M.Y.K.), Department of Pulmonary and Critical Care Medicine (S.P., C.M.C.), Department of Clinical Epidemiology & Biostatistics (H.J. Kim), and Department of Oncology (J.C.L., S.W.K., D.H.L., C.M.C.), Asan Medical Center, University of Ulsan College of Medicine, Olympic-ro 43 gil 88, Seoul 05505, Republic of Korea; Department of Pulmonary and Critical Care Medicine, Hallym University Dongtan Sacred Heart Hospital, Dongtan, Republic of Korea (S.P.); and Department of Radiology, Kyung Hee University Hospital at Gangdong, College of Medicine, Kyung Hee University, Seoul, Republic of Korea (H.N.L.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1148/radiol.2018180070DOI Listing
October 2018

Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy.

Lung Cancer 2018 08 24;122:234-242. Epub 2018 May 24.

Samsung Medical Center, Sungkyunkwan University School of Medicine, 81, Irwon-Ro, Gangnam-Gu, Seoul, 06351, Republic of Korea. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2018.05.023DOI Listing
August 2018

Ramucirumab Safety in East Asian Patients: A Meta-Analysis of Six Global, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trials.

J Glob Oncol 2018 Jul;4:1-12

Chia-Jui Yen, National Cheng Kung University Hospital, Tainan; Jin-Yuan Shih, National Taiwan University Hospital; Yee Chao, National Yang-Ming University and Taipei Veterans General Hospital; Rebecca Cheng, Eli Lilly and Company, Taipei, Taiwan; Kei Muro, Aichi Cancer Center Hospital, Nagoya; Masatoshi Kudo, Kindai University School of Medicine, Osaka-Sayama City, Osaka; Kentaro Yamazaki, Shizuoka Cancer Center, Shizuoka, Japan; Tae-Won Kim and Sang-We Kim, Asan Medical Center; JooHyuk Sohn and Hyun Cheol Chung, Yonsei University College of Medicine, Seoul; Keun-Wook Lee, Seoul National University College of Medicine, Seongnam, South Korea; Yawei Zhang and Polina Binder, Eli Lilly and Company, Bridgewater, NJ; Gu Mi, Eli Lilly and Company, Indianapolis, IN, USA; and Mauro Orlando, Eli Lilly and Company, Buenos Aires, Argentina.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JGO.17.00227DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223521PMC
July 2018

Prognosis of multi-level N2-positive non-small cell lung cancer according to lymph node staging using endobronchial ultrasound-transbronchial biopsy.

Thorac Cancer 2018 06 2;9(6):684-692. Epub 2018 Apr 2.

Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1759-7714.12629DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5983197PMC
June 2018

Afatinib in heavily pretreated advanced NSCLC patients who progressed following prior gefitinib or erlotinib: Compassionate use program in Korea.

Lung Cancer 2018 05 6;119:36-41. Epub 2018 Mar 6.

Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2018.02.020DOI Listing
May 2018

Mutational Profiling of Malignant Mesothelioma Revealed Potential Therapeutic Targets in EGFR and NRAS.

Transl Oncol 2018 Apr 3;11(2):268-274. Epub 2018 Feb 3.

Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul. Korea. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.tranon.2018.01.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884183PMC
April 2018

Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses.

J Clin Oncol 2017 Dec 2;35(36):4027-4034. Epub 2017 Oct 2.

Tony S.K. Mok, The Chinese University of Hong Kong, Prince of Wales Hospital, Sha Tin, Hong Kong, Special Administrative Region, People's Republic of China; Yi-Long Wu and Jin-Ji Yang, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou; Jie Wang, Peking University School of Oncology, Beijing Cancer Hospital and Institute, Beijing; You Lu, Sichuan University, Sichuan; Xiaojin Shi, AstraZeneca, Shanghai, People's Republic of China; James Chih-Hsin Yang, The National Taiwan University Hospital and College of Medicine, Taipei, Taiwan, Republic of China; Sang-We Kim, University of Ulsan College of Medicine; Myung-Ju Ahn, Sungkyunkwan University School of Medicine, Seoul, South Korea; Kazuhiko Nakagawa, Kindai University; Shinji Atagi, Kinkichuo Chest Medical Center, Osaka, Japan; Santiago Ponce, Hospital Universitario 12 de Octubre, Madrid, Spain; Yuri Rukazenkov, AstraZeneca, Cambridge; Vincent Haddad, AstraZeneca, Royston, United Kingdom; Kenneth S. Thress, AstraZeneca, Waltham, MA; and Jean-Charles Soria, Gustave Roussy Cancer Campus and University Paris-Sud, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.73.9250DOI Listing
December 2017

HSP90 inhibitor (NVP-AUY922) enhances the anti-cancer effect of BCL-2 inhibitor (ABT-737) in small cell lung cancer expressing BCL-2.

Cancer Lett 2017 12 4;411:19-26. Epub 2017 Oct 4.

Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, 05505, Republic of Korea. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2017.09.040DOI Listing
December 2017

The HSP90 inhibitor, NVP-AUY922, attenuates intrinsic PI3K inhibitor resistance in KRAS-mutant non-small cell lung cancer.

Cancer Lett 2017 10 7;406:47-53. Epub 2017 Aug 7.

Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 05505, Republic of Korea. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2017.07.028DOI Listing
October 2017

Comments on the trial of cisplatin and etoposide plus thoracic radiotherapy followed by nivolumab or placebo for locally advanced non-small cell lung cancer (RTOG 3505).

J Thorac Dis 2017 Oct;9(10):3525-3528

Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd.2017.09.12DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5723812PMC
October 2017

Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial.

J Clin Oncol 2017 Aug 5;35(22):2490-2498. Epub 2017 May 5.

Dong-Wan Kim, Seoul National University Hospital; Myung-Ju Ahn, Samsung Medical Center; Sang-We Kim, Asan Medical Center, Seoul, South Korea; Marcello Tiseo, University Hospital of Parma, Parma, Italy; Karen L. Reckamp, City of Hope, Duarte, CA; Karin Holmskov Hansen, Odense University Hospital, Odense, Denmark; Rudolf M. Huber, University Hospital of Munich, German Centre for Lung Research, Munich, Germany; Howard L. West, Swedish Cancer Institute, Seattle, WA; Harry J.M. Groen, University of Groningen, University Medical Center Groningen, Groningen; Egbert F. Smit, VU University Medical Center, Amsterdam, the Netherlands; Maximilian J. Hochmair, Otto Wagner Hospital, Vienna, Austria; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Scott N. Gettinger, Yale Cancer Center, New Haven, CT; Corey J. Langer, University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Luis G. Paz-Ares Rodríguez, Hospital Universitario 12 de Octubre, Madrid, Spain; Edward S. Kim, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC; William Reichmann, Frank G. Haluska, and David Kerstein, ARIAD Pharmaceuticals, Cambridge, MA; and D. Ross Camidge, University of Colorado Cancer Center, Aurora, CO.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.71.5904DOI Listing
August 2017

Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.

J Clin Oncol 2017 Apr 21;35(12):1288-1296. Epub 2017 Feb 21.

James Chih-Hsin Yang and Chia-Chi Lin, National Taiwan University Hospital, Taipei; Wu-Chou Su, National Cheng Kung University Hospital, Tainan, Taiwan, Republic of China; Myung-Ju Ahn, Sungkyunkwan University; Dong-Wan Kim, Seoul National University Hospital; Sang-We Kim, Asan Medical Center, Seoul; Joo-Hang Kim, CHA University, Gyeonggi-do, Republic of Korea; Suresh S. Ramalingam, Emory University School of Medicine, Atlanta, GA; Lecia V. Sequist, Massachusetts General Hospital; Pasi A. Jänne, Dana-Farber Cancer Institute, Boston, MA; David Planchard, Institut Gustave Roussy, Villejuif, France; Enriqueta Felip, Vall d'Hebron University Hospital, Barcelona, Spain; Fiona Blackhall, The Christie Hospital; University of Manchester, Manchester; Helen Mann and Serban Ghiorghiu, AstraZeneca, Cambridge; Mireille Cantarini, AstraZeneca, Macclesfield, United Kingdom; Daniel Haggstrom, Carolinas Healthcare System, Charlotte, NC; Kiyotaka Yoh, National Cancer Center Hospital East, Kashiwa, Chiba; Tomonori Hirashima, Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Osaka, Japan; Silvia Novello, University of Turin, Turin, Italy; and Kathryn Gold, University of California San Diego Moores Cancer Center, San Diego, CA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2016.70.3223
Publisher Site
http://dx.doi.org/10.1200/JCO.2016.70.3223DOI Listing
April 2017

Epidermal growth factor receptor mutations and brain metastasis in patients with nonadenocarcinoma of the lung.

J Cancer Res Ther 2016 Jan-Mar;12(1):318-22

Department of Internal Medicine, Division of Hematology and Oncology, Cancer Center Hospital, Institute of Radiological and Medical Sciences, Seoul, Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/0973-1482.154024DOI Listing
December 2016

Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.

J Clin Oncol 2016 11;34(31):3740-3748

Martin Reck, LungenClinic Grosshansdorf, Airway Research Center North, Grosshansdorf; Michael Thomas, Translational Lung Research Center Heidelberg, Thoraxklinik im Universitätsklinikum Heidelberg, Heidelberg, Germany; Alexander Luft, Leningrad Regional Clinical Hospital, Leningrad, Russia; Aleksandra Szczesna, Mazowieckie Centrum Leczenia Chorob Pluc i Gruzlicy w Otwocku, Otwocku, Poland; Libor Havel, Hospital Na Bulovce, Prague, Czech Republic; Sang-We Kim, Asan Medical Center and University of Ulsan College of Medicine, Seoul, Korea; Wallace Akerley, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Maria Catherine Pietanza, Memorial Sloan Kettering Cancer Center, New York, NY; Kathryn Gold, University of Texas MD Anderson Cancer Center, Houston, TX; Leora Horn, Vanderbilt-Ingram Cancer Center; David Spigel, Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN; Anne Pieters, Teresa Kong Sanchez, and Justin Fairchild, Bristol-Myers Squibb, Princeton, NJ; Yi-long Wu, Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong, People's Republic of China; Christoph Zielinski, Medical University of Vienna, Vienna, Austria; Enriqueta Felip, Vall d'Hebron University Hospital, Barcelona, Spain; Joachim Aerts, Erasmus MC Cancer Institute, Rotterdam, the Netherlands; Kazuhiko Nakagawa, Kinki University Hospital, Osaka, Japan; and Paul Lorigan, the Christie NHS Foundation Trust, Manchester, United Kingdom.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2016.67.6601
Publisher Site
http://dx.doi.org/10.1200/JCO.2016.67.6601DOI Listing
November 2016

Predictive factors for a long-term response duration in non-squamous cell lung cancer patients treated with pemetrexed.

BMC Cancer 2016 07 7;16:417. Epub 2016 Jul 7.

Department of Oncology, University of Ulsan, College of Medicine, Asan Medical Center, 388-1 Pungnap-Dong, Songpa-gu, Seoul, 05505, South Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-016-2457-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4936194PMC
July 2016

The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.

Cancer Lett 2016 Mar 23;372(1):75-81. Epub 2015 Dec 23.

Institute for Innovative Cancer Research, College of Medicine, Asan Medical Center, University of Ulsan, Seoul 138-736, Republic of Korea; Department of Oncology, Asan Medical Center, Seoul, Republic of Korea. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2015.12.015DOI Listing
March 2016

A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806).

Lung Cancer 2016 Mar 29;93:1-8. Epub 2015 Dec 29.

Division of Medical Oncology, Department of Internal Medicine, CHA University Bundang Medical Center, Seongnam, South Korea; Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2015.12.005DOI Listing
March 2016

Definitive radiotherapy with or without chemotherapy for clinical stage T4N0-1 non-small cell lung cancer.

Radiat Oncol J 2015 Dec 30;33(4):284-93. Epub 2015 Dec 30.

Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3857/roj.2015.33.4.284DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4707211PMC
December 2015

Bone metastasis in pulmonary sclerosing hemangioma.

Korean J Intern Med 2015 Nov 30;30(6):928-30. Epub 2015 Oct 30.

Division of Oncology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

View Article

Download full-text PDF

Source
http://www.kjim.org/upload/kjim-30-6-928.pdf
Web Search
http://kjim.org/journal/view.php?doi=10.3904/kjim.2015.30.6.
Publisher Site
http://dx.doi.org/10.3904/kjim.2015.30.6.928DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4642025PMC
November 2015

Survival Benefit of Pemetrexed in Lung Adenocarcinoma Patients With Anaplastic Lymphoma Kinase Gene Rearrangements.

Clin Lung Cancer 2015 Sep 10;16(5):e83-9. Epub 2015 Jan 10.

Department of Oncology, University of Ulsan, College of Medicine, Asan Medical Center, Seoul, South Korea. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2015.01.003DOI Listing
September 2015

Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04.

J Clin Oncol 2015 Aug 6;33(24):2660-6. Epub 2015 Jul 6.

Jin Seok Ahn, Yong Chan Ahn, Yoon-La Choi, Jong-Mu Sun, Myung-Ju Ahn, and Keunchil Park, Samsung Medical Center, Sungkyunkwan University School of Medicine; Joo-Hang Kim and Chang Geol Lee, Yonsei Cancer Center, Yonsei University Health System; Dong-Wan Kim, Seoul National University Hospital; Jin-Hyoung Kang, Catholic University Seoul St Mary's Hospital; Sung Rok Kim, Inje University Sanggye Paik Hospital; Sang-We Kim, Asan Medical Center, University of Ulsan College of Medicine; Sin-Ho Jung, Samsung Medical Center, Office of Biomedical Science, Seoul; Eun Kyung Cho and Kyu Chan Lee, Gachon University Gil Medical Center, Incheon; Hoon-Kyo Kim, Catholic University St Vincent's Hospital; Jin-Hyuck Choi, Ajou University Hospital, Suwon; Young Joo Min, Ulsan University Hospital, Ulsan; Kyung Hee Lee, Yeungnam University Medical Center; Hong Suk Song, Keimyung University Dongsan Medical Center, Daegu, Korea; Ming Chen, Sun Yat-Sen University Cancer Center, Guangzhou; Guangying Zhu, Beijing Cancer Hospital, Beijing; Yi-Long Wu, Guandong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangdong, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.60.0130DOI Listing
August 2015

Clinical significance of NQO1 polymorphism and expression of p53, SOD2, PARP1 in limited-stage small cell lung cancer.

Int J Clin Exp Pathol 2014 15;7(10):6743-51. Epub 2014 Sep 15.

Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine Seoul, South Korea ; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine Seoul, South Korea.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4230145PMC
July 2015

Genomic Alterations in the RB Pathway Indicate Prognostic Outcomes of Early-Stage Lung Adenocarcinoma.

Clin Cancer Res 2015 Jun 7;21(11):2613-23. Epub 2014 Oct 7.

Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea. Center for Cancer Genome Discovery, Asan Institute for Life Science, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-0519DOI Listing
June 2015

Multiple resistant factors in lung cancer with primary resistance to EGFR-TK inhibitors confer poor survival.

Lung Cancer 2015 May 12;88(2):139-46. Epub 2015 Feb 12.

Department of Oncology, Asan Medical Center, College of Medicine, University of Ulsan, Seoul, Republic of Korea. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2015.01.023DOI Listing
May 2015

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

N Engl J Med 2015 Apr;372(18):1689-99

From the Lowe Center for Thoracic Oncology and the Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute, Boston (P.A.J.); National Taiwan University and National Taiwan University Hospital (J.C.-H.Y.) and Cheng Kung University Hospital (W.-C.S.) - both in Taipei, Taiwan; Seoul National University Hospital (D.-W.K.), Samsung Medical Center (M.-J.A.), Asan Medical Center (S.-W.K.), and Yonsei Cancer Center, Yonsei University Health System (J.-H.K.) - all in Seoul, South Korea; Institut Gustave Roussy, Villejuif, France (D.P.); National Cancer Center Hospital, Tokyo (Y.O.); Winship Cancer Institute of Emory University, Atlanta (S.S.R.); Vanderbilt Ingram Cancer Center, Nashville (L.H.); Levine Cancer Institute, Carolinas Healthcare System, Charlotte, NC (D.H.); Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona (E.F.); and AstraZeneca, Macclesfield (P.F., M.C., K.H.B., P.A.D., S.G.), and University of Manchester, Christie Hospital, Manchester (M.R.) - both in the United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1411817DOI Listing
April 2015

EGFR-TKI is effective regardless of treatment timing in pulmonary adenocarcinoma with EGFR mutation.

Cancer Chemother Pharmacol 2015 Jan 25;75(1):197-206. Epub 2014 Nov 25.

Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 86, Asanbyeongwon-gil, Songpa-gu, Seoul, 138-736, Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-014-2631-5DOI Listing
January 2015

Outcomes and prognostic factors of patients with lung cancer and pneumonia-induced respiratory failure in a medical intensive care unit: a single-center study.

J Crit Care 2014 Jun 13;29(3):414-9. Epub 2014 Jan 13.

Department of Pulmonary and Critical Care Medicine, Asan Medical Center, College of Medicine, University of Ulsan, 86 Asanbyeongwon-gil, Songpa-gu, Seoul, 138-736, South Korea. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jcrc.2014.01.005DOI Listing
June 2014

Postoperative radiation therapy following the incomplete resection of a non-small cell lung cancer.

Radiat Oncol J 2014 Jun 30;32(2):70-6. Epub 2014 Jun 30.

Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3857/roj.2014.32.2.70DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4104222PMC
June 2014

A randomized, phase II study of vandetanib maintenance for advanced or metastatic non-small-cell lung cancer following first-line platinum-doublet chemotherapy.

Lung Cancer 2013 Dec 8;82(3):455-60. Epub 2013 Sep 8.

Department of Medicine, Samsung Medical Center, Sungkyunkwan University, 50 Irwon-dong, Gangnam-gu, Seoul 135-710, Republic of Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2013.08.027DOI Listing
December 2013

Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer.

BMC Cancer 2013 Dec 27;13:606. Epub 2013 Dec 27.

Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Seoul, Songpa-gu, Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1471-2407-13-606DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3877961PMC
December 2013

A pilot study for the early assessment of the effects of BMS-754807 plus gefitinib in an H292 tumor model by [(18)F]fluorothymidine-positron emission tomography.

Invest New Drugs 2013 Jun 18;31(3):506-15. Epub 2012 Sep 18.

Institute for Innovative Cancer Research, Asan Institute for Life Science, Asan Medical Center, Olympic-ro 43-gil, Songpa-gu, Seoul, 138-736, Korea.

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007/s10637-012-9874
Web Search
http://link.springer.com/10.1007/s10637-012-9874-y
Publisher Site
http://dx.doi.org/10.1007/s10637-012-9874-yDOI Listing
June 2013

The extended leukocyte differential count using the Cytodiff flow cytometric system reveals that higher CD16+ cytotoxic NK+T lymphocyte levels predict superior survival outcomes in patients with metastatic carcinoma.

Cytometry B Clin Cytom 2013 May 26;84(3):202-4. Epub 2012 Dec 26.

Department of Laboratory Medicine, University of Ulsan College of Medicine and Asan Medical Center, Seoul, South Korea.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cyto.b.21063
Publisher Site
http://dx.doi.org/10.1002/cyto.b.21063DOI Listing
May 2013

Clinical prognostic factors and grading system for rib fracture following stereotactic body radiation therapy (SBRT) in patients with peripheral lung tumors.

Lung Cancer 2013 Feb 20;79(2):161-6. Epub 2012 Nov 20.

Department of Radiation Oncology, Asan Medical Center, University of Ulsan, College of Medicine, Seoul, Republic of Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2012.10.011DOI Listing
February 2013

The role of integrated 18F-FDG PET-CT as a staging tool for limited-stage small cell lung cancer: a retrospective study.

Onkologie 2012 3;35(7-8):432-8. Epub 2012 Jul 3.

Departments of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000341073DOI Listing
January 2013

Phase II study of pemetrexed plus oxaliplatin for platinum-resistant advanced or metastatic non-small cell lung cancer patients.

Med Oncol 2012 Jun 16;29(2):640-3. Epub 2011 Apr 16.

Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, 388-1 Pungnap-2 dong, Songpa-gu, 138736 Seoul, Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12032-011-9944-6DOI Listing
June 2012

Angiosarcomas of the bilateral breast and heart: which one is the primary site?

Korean J Intern Med 2012 Jun 31;27(2):224-8. Epub 2012 May 31.

Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3904/kjim.2012.27.2.224DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3372809PMC
June 2012

Phase II Study of S-1 Plus Either Irinotecan or Docetaxel for Non-small Cell Lung Cancer Patients Treated with More Than Three Lines of Treatment.

Cancer Res Treat 2011 Dec 27;43(4):212-6. Epub 2011 Dec 27.

Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4143/crt.2011.43.4.212DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3253862PMC
December 2011

Erlotinib in first-line therapy for non-small cell lung cancer: a prospective phase II study.

Anticancer Res 2011 Oct;31(10):3457-62

Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, 388-1 Pungnap-2 dong, Songpa-gu, Seoul 138-736, Korea.

View Article

Download full-text PDF

Source
October 2011

FDG-PET as a potential tool for selecting patients with advanced non-small cell lung cancer who may be spared maintenance therapy after first-line chemotherapy.

Clin Cancer Res 2011 Aug 14;17(15):5093-100. Epub 2011 Jun 14.

Departments of Oncology and Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-10-2791DOI Listing
August 2011

Limited role of interim PET/CT in patients with diffuse large B-cell lymphoma treated with R-CHOP.

Ann Hematol 2011 Jul 22;90(7):797-802. Epub 2010 Dec 22.

Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Souel, South Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-010-1135-6DOI Listing
July 2011

An indirect comparison of bevacizumab plus cisplatin-gemcitabine and cisplatin plus pemetrexed treatment for patients with advanced first-line non-squamous non-small cell lung cancer in East Asia.

Asia Pac J Clin Oncol 2011 Jun;7 Suppl 2:13-21

Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, Linkou, Chang Gung University College of Medicine Taoyuan, Taiwan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1743-7563.2011.01398.xDOI Listing
June 2011

Cost-effectiveness of bevacizumab-based therapy versus cisplatin plus pemetrexed for the first-line treatment of advanced non-squamous NSCLC in Korea and Taiwan.

Asia Pac J Clin Oncol 2011 Jun;7 Suppl 2:22-33

Section of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1743-7563.2011.01399.xDOI Listing
June 2011

False-positive hypermetabolic lesions on post-treatment PET-CT after influenza vaccination.

Korean J Intern Med 2011 Jun 1;26(2):210-2. Epub 2011 Jun 1.

Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3904/kjim.2011.26.2.210DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3110855PMC
June 2011

Initial cytoreductive treatment with thalidomide plus bolus vincristine/doxorubicin and reduced dexamethasone followed by autologous stem cell transplantation for multiple myeloma.

Invest New Drugs 2011 Feb 13;29(1):175-81. Epub 2009 Oct 13.

Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-009-9343-4DOI Listing
February 2011

BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: a single center comparative analysis of efficacy and toxicity.

Leuk Res 2011 Feb 3;35(2):183-7. Epub 2010 Aug 3.

Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 86 Asan byeongwon-gil, Songpa-gu, 138-736 Seoul, Republic of Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2010.07.016DOI Listing
February 2011

Phase II study of erlotinib for chemotherapy-naïve patients with advanced or metastatic non-small cell lung cancer who are ineligible for platinum doublets.

Cancer Chemother Pharmacol 2011 Jan 25;67(1):35-9. Epub 2010 Feb 25.

Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, 388-1 Pungnap-2 dong, Songpa-gu, Seoul 138-736, Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-010-1280-6DOI Listing
January 2011

Chemotherapy for advanced non-small-cell lung cancer patients with poor performance.

Expert Rev Clin Pharmacol 2010 Sep;3(5):623-6

Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 86, Asanbyeongwon-gil, Songpa-gu, Seoul, 138-736, Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/ecp.10.48DOI Listing
September 2010

Modified number of extranodal involved sites as a prognosticator in R-CHOP-treated patients with disseminated diffuse large B-cell lymphoma.

Korean J Intern Med 2010 Sep 31;25(3):301-8. Epub 2010 Aug 31.

Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3904/kjim.2010.25.3.301DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2932944PMC
September 2010

Ki-67 expression as a prognostic factor in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP.

Eur J Haematol 2010 Aug 6;85(2):149-57. Epub 2010 May 6.

Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1600-0609.2010.01467.xDOI Listing
August 2010

Serum albumin level is a significant prognostic factor reflecting disease severity in symptomatic multiple myeloma.

Ann Hematol 2010 Apr 21;89(4):391-7. Epub 2009 Oct 21.

Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 86 Asan Byeongwon gil, Songpa-gu, Seoul, 138-736, South Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-009-0841-4DOI Listing
April 2010

Flow cytometric detection of platelet-associated immunoglobulin in patients with immune thrombocytopenic purpura and nonimmune thrombocytopenia.

Ann Clin Lab Sci 2009 ;39(3):283-8

Department of Laboratory Medicine, University of Ulsan, Asan Medical Center, Seoul, Korea.

View Article

Download full-text PDF

Source
December 2009

Reproducibility of the kinetic analysis of 3'-deoxy-3'-[(18)F]fluorothymidine positron emission tomography in mouse tumor models.

Nucl Med Biol 2009 Oct 29;36(7):711-9. Epub 2009 Jul 29.

Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul 138-736, South Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.nucmedbio.2009.06.001DOI Listing
October 2009

Erlotinib monotherapy for stage IIIB/IV non-small cell lung cancer: a multicenter trial by the Korean Cancer Study Group.

J Thorac Oncol 2009 Sep;4(9):1136-43

Division of Hematology/Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0b013e3181b270a7DOI Listing
September 2009